Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 05, 2015 1:00 PM ET

Healthcare Equipment and Supplies

Company Overview of Solace Therapeutics, Inc.

Company Overview

Solace Therapeutics, Inc., a medical device company, engages in the development of non-surgical office based treatments for common bladder disorders in the United States. It develops products for various bladder disorders, such as stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. The company was incorporated in 2002 and is based in Newton, Massachusetts.

135 Newbury Street

Framingham, MA 01701

United States

Founded in 2002



Key Executives for Solace Therapeutics, Inc.

Chief Executive Officer and President
Vice President of R&D
Vice President of Marketing
Compensation as of Fiscal Year 2014.

Solace Therapeutics, Inc. Key Developments

Solace Therapeutics Announces Enrollment of First Patient in the Stress Urinary Incontinence Control Efficacy and Safety Study Pivotal Trial

Solace Therapeutics, Inc. announced the company has begun patient enrollment in the SUCCESS Clinical Trial (Stress Urinary InContinence Control Efficacy and Safety Study). The first patient was enrolled by Jeffrey A. Snyder M.D., with Genitourinary Surgical Consultants in Denver, Colorado to Assess Safety and Effectiveness of the Solace Bladder Control Balloon System(TM) for the treatment of Stress Urinary Incontinence (SUI) in Women.

Solace Therapeutics Announces Data from Multicenter 166 Patient Randomized Controlled Study

Solace Therapeutics, Inc. announced that data from a multicenter 166 patient randomized controlled study has been published in the December issue of the Journal of Urology. The study demonstrates the safety and effectiveness of limiting rapid pressure changes within the bladder to reduce symptoms of Stress Urinary Incontinence (SUI). Composite end point results (pad weight reduction and quality of life improvement) from this trial showed statistically significant benefit when compared to a sham therapy. The percentage of patients in this study with a greater than 50% decrease in incontinence episode frequency (65.5% treatment vs. 31.3% control) compared favorably to reported results for Botox for overactive bladder (57.5% treatment vs. 28.9% control). Women with SUI typically experience transient increases in intravesical pressure during physical movement including coughing, laughing, sneezing, or during exercise. When this increased bladder pressure exceeds the ability of the urethra to withstand pressure, leakage occurs. Unlike currently available SUI treatments that focus on improving the urethral closure forces, Solace reduces bladder pressure increases with the placement of a compressible air-filled balloon in the bladder. The balloon acts like a "shock-absorber" to prevent rapid changes in pressure and reduce leakage. The un-inflated balloon is placed into the bladder through the urethra and filled in an office procedure without the need for anesthesia. When necessary, the balloon is deflated and removed in a similar office procedure.

Solace Therapeutics Appoints Stacy Enxing Seng as Board of Directors

Solace Therapeutics announced that Stacy Enxing Seng has joined the Board of Directors. She serves on the board alongside Ryan Drant, General Partner with New Enterprise Associates (NEA); Ali Behbahani MD, Principal at NEA; John McDonough, CEO at T2 Biosystems; and Kevin G. Connors, founding partner of Spray Venture Partners. Enxing Seng is President of Covidien's Vascular Therapies Global Business Unit.

Similar Private Companies By Industry

Company Name Region
Snia S.p.A. Carbomedics, Inc. United States
U-Systems, Inc. United States
Qualgenix LLC United States
Mevion Medical Systems, Inc. United States
Precision Endoscopic Technologies LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Solace Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at